Subscribe to our newsletter to receive the latest product updates and special offers

Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Revenue Breakdown and Options Chain

Gain deeper insights into company revenues with a detailed analysis of revenue sources.
Explore the updated Options feature, providing in-depth data, and a 3D viewing option.

Last Close
Mar 28 04:00PM ET
17.51
Dollar change
0.00
Percentage change
0.00
%
IndexRUT P/E- EPS (ttm)-5.32 Insider Own11.02% Shs Outstand62.77M Perf Week-6.76%
Market Cap1.10B Forward P/E- EPS next Y-4.53 Insider Trans7.39% Shs Float55.85M Perf Month-13.19%
Income-237.73M PEG- EPS next Q-1.09 Inst Own90.43% Short Float13.64% Perf Quarter-22.18%
Sales0.31M P/S3545.49 EPS this Y15.57% Inst Trans19.41% Short Ratio7.76 Perf Half Y13.92%
Book/sh4.36 P/B4.01 EPS next Y-0.95% ROA-51.37% Short Interest7.62M Perf Year-30.07%
Cash/sh7.61 P/C2.30 EPS next 5Y- ROE-56.80% 52W Range10.93 - 30.30 Perf YTD-19.61%
Dividend Est.- P/FCF- EPS past 5Y20.35% ROI-51.32% 52W High-42.21% Beta1.10
Dividend TTM- Quick Ratio18.26 Sales past 5Y-12.71% Gross Margin-321.02% 52W Low60.27% ATR (14)1.11
Dividend Ex-Date- Current Ratio18.26 EPS Y/Y TTM-32.05% Oper. Margin-81035.35% RSI (14)44.87 Volatility4.99% 6.41%
Employees96 Debt/Eq0.05 Sales Y/Y TTM-82.28% Profit Margin-75711.46% Recom1.00 Target Price38.27
Option/ShortYes / Yes LT Debt/Eq0.05 EPS Q/Q-19.17% Payout- Rel Volume1.03 Prev Close17.51
Sales Surprise-53.31% EPS Surprise-38.07% Sales Q/Q-31.43% EarningsFeb 27 AMC Avg Volume981.51K Price17.51
SMA20-3.83% SMA50-6.91% SMA200-5.85% Trades Volume1,010,496 Change0.00%
Date Action Analyst Rating Change Price Target Change
Jun-14-23Resumed Credit Suisse Outperform $51
Jun-14-23Initiated BTIG Research Buy $46
May-30-23Initiated RBC Capital Mkts Outperform $44
Apr-17-23Initiated Wells Fargo Overweight $46
Mar-30-23Initiated Stifel Buy $49
Dec-19-22Initiated Needham Buy $45
Dec-19-22Initiated Cowen Outperform $45
Dec-16-22Initiated Credit Suisse Outperform $51
Dec-01-22Initiated H.C. Wainwright Buy $35
Jun-23-22Initiated B. Riley Securities Buy $25
Mar-06-24 04:01PM
Mar-05-24 08:00AM
Feb-28-24 09:55AM
Feb-27-24 04:01PM
Feb-16-24 08:00AM
04:01PM Loading…
Feb-06-24 04:01PM
Jan-17-24 10:00PM
04:01PM
Jan-08-24 08:00AM
Jan-04-24 08:00AM
Dec-18-23 07:00AM
Nov-21-23 08:00AM
Nov-13-23 05:00PM
04:01PM
Nov-08-23 08:00AM
08:00AM Loading…
Nov-03-23 08:00AM
Oct-30-23 08:30AM
Oct-26-23 08:00AM
Sep-25-23 08:00AM
Sep-07-23 08:00AM
Aug-08-23 04:01PM
Aug-04-23 04:01PM
Jul-10-23 04:01PM
Jul-06-23 04:05PM
Jun-13-23 08:00AM
Jun-05-23 04:05PM
May-09-23 04:01PM
May-08-23 08:00AM
May-04-23 04:05PM
May-02-23 08:00AM
01:41PM Loading…
Apr-20-23 01:41PM
08:00AM
Apr-16-23 09:50AM
Apr-13-23 06:52AM
Apr-12-23 08:00AM
Apr-04-23 04:05PM
Mar-08-23 07:00AM
Mar-07-23 08:00AM
Mar-03-23 04:05PM
Mar-01-23 08:00AM
Feb-28-23 08:00AM
Feb-07-23 08:00AM
Feb-06-23 07:00AM
Feb-02-23 04:05PM
Jan-08-23 08:00AM
Jan-05-23 04:05PM
Jan-03-23 08:00AM
Dec-21-22 07:00AM
Dec-07-22 04:05PM
Nov-28-22 07:00AM
Nov-16-22 05:10AM
Nov-14-22 07:01AM
06:59AM
Nov-08-22 07:05AM
07:00AM
Oct-22-22 02:04PM
Oct-12-22 08:12AM
Sep-02-22 08:00AM
Aug-31-22 08:00AM
Aug-25-22 04:03PM
Aug-17-22 08:59AM
06:00AM
Aug-15-22 04:35PM
04:01PM
02:17PM
07:02AM
06:59AM
Aug-08-22 08:00AM
Aug-05-22 08:00AM
Jul-08-22 08:00AM
Jun-23-22 07:00AM
Jun-03-22 08:00AM
Jun-01-22 08:00AM
May-12-22 04:05PM
May-03-22 08:00AM
Apr-06-22 08:00AM
Apr-04-22 04:05PM
Mar-21-22 04:05PM
Mar-14-22 06:36PM
04:05PM
Mar-10-22 04:05PM
10:33AM
Mar-03-22 04:16PM
Feb-14-22 08:00AM
Jan-31-22 07:00AM
Jan-04-22 07:00AM
Dec-20-21 07:00AM
Nov-30-21 08:00AM
Nov-15-21 07:00AM
Nov-04-21 04:05PM
Nov-03-21 04:05PM
Oct-14-21 08:00AM
Sep-30-21 08:06AM
Sep-23-21 04:01PM
Sep-21-21 12:22AM
Sep-20-21 04:01PM
Aug-23-21 02:36PM
Aug-11-21 07:00AM
Aug-05-21 08:30AM
Jul-26-21 07:30AM
Viridian Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in the development of proprietary RNA-targeted therapeutics. Its product candidates include Cobomarsen, which treats patients with certain cancers, including cutaneous T-cell lymphoma and adult T-cell leukemia/lymphoma, and Remlarsen and MRG-229, which are made for the treatment of patients with pathological fibrosis. The company was founded by William S. Marshall and Bruce L. Booth in February 2006 and is headquartered in Waltham, MA.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Fairmount Funds Management LLCDirectorJan 22 '24Buy21.00476,1909,999,9901,839,954Jan 24 06:44 PM
Meisner LaraChief Legal OfficerJun 16 '23Option Exercise23.032762229,998Jun 20 05:23 PM
Meisner LaraChief Legal OfficerJun 16 '23Sale28.352776529,971Jun 20 05:23 PM
Meisner LaraChief Legal OfficerJun 15 '23Option Exercise23.032,26952,25532,240Jun 20 05:23 PM
Meisner LaraChief Legal OfficerJun 15 '23Sale28.022,26963,57729,971Jun 20 05:23 PM
Meisner LaraChief Legal OfficerJun 06 '23Option Exercise18.515,12694,88235,097Jun 06 07:41 PM
Meisner LaraChief Legal OfficerJun 06 '23Sale25.025,126128,25329,971Jun 06 07:41 PM
Meisner LaraChief Legal OfficerJun 05 '23Option Exercise18.514999,23630,470Jun 06 07:41 PM
Meisner LaraChief Legal OfficerJun 05 '23Sale25.0349912,49029,971Jun 06 07:41 PM
Meisner LaraChief Legal OfficerJun 02 '23Option Exercise14.001,87526,25031,846Jun 06 07:41 PM
Meisner LaraChief Legal OfficerJun 02 '23Sale24.211,87545,39429,971Jun 06 07:41 PM
Myers Scott DunsethChief Executive OfficerApr 12 '23Buy25.374,000101,479259,500Apr 12 07:05 PM